1. A vaccine composition containing an antigen for transdermal administration for use in stimulating cellular immunity, where transdermal administration of the composition provides a relative number of Th1 cells in model animals used for immunological evaluation, which was introduced a composition of 10% or more. The vaccine composition according to claim 1, wherein the composition is intended for use in the treatment of cancer. The vaccine composition according to claim 1, wherein the composition is intended for use in the treatment of a viral disease. The vaccine composition according to claim 1, wherein the composition comprises at least one cell immunity stimulation promoter selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide, and a low molecular weight immunomodulating drug. The vaccine composition according to claim 4, where the promoter of the stimulation of cellular immunity is a helper peptide. The vaccine composition according to claim 4, wherein the promoter of the stimulation of cellular immunity is a combination of a helper peptide and at least one substance selected from the group consisting of a TLR ligand, a cyclic dinucleotide and a low molecular weight immunomodulating preparation. The vaccine composition according to claim 1, which is administered in a state of mild irritation. The vaccine composition of claim 7, wherein the mild irritation state is a condition in which transepidermal water loss (TEWL) in model animals used to evaluate skin irritation is 50 g / mile below before administration of the composition. The vaccine composition of claim 7, wherein the mild irritation state is a condition in which the level of cutaneous TEWL is in fashion1. Вакцинная композиция, содержащая антиген для чрескожного введения для применения в стимуляции клеточного иммунитета, где чрескожное введение композиции обеспечивает относительное число Th1-клеток на модельных животных, использованных для иммунологической оценки, к
